A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab

• Status: Not yet recruiting
• Trial end date: 2024-01-11
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Celgene

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com

Inclusion Criteria:

• Active Eosinophilic esophagitis (EoE) with histologic evidence as a peak count of ≥ 15 eosinophils per higher-power field at any 2 levels of the esophagus

• Previously received an adequate trial of proton-pump inhibitor medication that did not provide complete response to EoE

• EoE symptoms documented in daily diary during the screening period

Exclusion Criteria:

• On a regimen of therapeutic anticoagulation

• Demonstrates evidence of immunosuppression or is receiving systemic immunosuppressive or immunomodulating drugs

• Currently receiving a high potency topical corticosteroid for dermatologic use

Other protocol-defined inclusion/exclusion criteria apply